These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 26382310)

  • 1. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society.
    Menopause; 2015 Nov; 22(11):1155-72; quiz 1173-4. PubMed ID: 26382310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2023 nonhormone therapy position statement of The North American Menopause Society.
    “The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society” Advisory Panel
    Menopause; 2023 Jun; 30(6):573-590. PubMed ID: 37252752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.
    North American Menopause Society
    Menopause; 2004; 11(1):11-33. PubMed ID: 14716179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment strategies for reducing the burden of menopause-associated vasomotor symptoms.
    Umland EM
    J Manag Care Pharm; 2008 Apr; 14(3 Suppl):14-9. PubMed ID: 18439062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 2017 hormone therapy position statement of The North American Menopause Society.
    Menopause; 2018 Nov; 25(11):1362-1387. PubMed ID: 30358733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing risks and benefits of nonhormonal treatments for vasomotor symptoms in perimenopausal and postmenopausal women.
    Thacker HL
    J Womens Health (Larchmt); 2011 Jul; 20(7):1007-16. PubMed ID: 21675874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 2017 hormone therapy position statement of The North American Menopause Society.
    The NAMS 2017 Hormone Therapy Position Statement Advisory Panel
    Menopause; 2017 Jul; 24(7):728-753. PubMed ID: 28650869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone Therapy and Other Treatments for Symptoms of Menopause.
    Hill DA; Crider M; Hill SR
    Am Fam Physician; 2016 Dec; 94(11):884-889. PubMed ID: 27929271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.
    Menopause; 2013 Sep; 20(9):888-902; quiz 903-4. PubMed ID: 23985562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal and nonhormonal treatment of vasomotor symptoms.
    Krause MS; Nakajima ST
    Obstet Gynecol Clin North Am; 2015 Mar; 42(1):163-79. PubMed ID: 25681847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.
    Cobin RH; Goodman NF;
    Endocr Pract; 2017 Jul; 23(7):869-880. PubMed ID: 28703650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptoms of menopause: hot flushes.
    Santoro N
    Clin Obstet Gynecol; 2008 Sep; 51(3):539-48. PubMed ID: 18677148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of the Vasomotor Symptoms of Menopause: Twofers in Your Clinical Toolbox.
    Kling JM; Stuenkel CA; Faubion SS
    Mayo Clin Proc; 2024 Jul; 99(7):1142-1148. PubMed ID: 38960498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating vasomotor symptoms of menopause: the nurse practitioner's perspective.
    Alexander IM; Moore A
    J Am Acad Nurse Pract; 2007 Mar; 19(3):152-63. PubMed ID: 17341283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010).
    North American Menopause Society
    Menopause; 2011 Jul; 18(7):732-53. PubMed ID: 21685820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine.
    Umland EM; Falconieri L
    Int J Womens Health; 2012; 4():305-19. PubMed ID: 22870045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical appraisal of paroxetine for the treatment of vasomotor symptoms.
    Carroll DG; Lisenby KM; Carter TL
    Int J Womens Health; 2015; 7():615-24. PubMed ID: 26124682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond Estrogen: Treatment Options for Hot Flashes.
    McGarry K; Geary M; Gopinath V
    Clin Ther; 2018 Oct; 40(10):1778-1786. PubMed ID: 30217591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical, geospatial, and temporal diffusion of the 2015 North American Menopause Society position statement on nonhormonal management of vasomotor symptoms.
    Carpenter JS; Laine T; Harrison B; LePage M; Pierce T; Hoteling N; Börner K
    Menopause; 2017 Oct; 24(10):1154-1159. PubMed ID: 28538600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paroxetine: a first for selective serotonin reuptake inhibitors - a new use: approved for vasomotor symptoms in postmenopausal women.
    Weber L; Thacker HL
    Womens Health (Lond); 2014 Mar; 10(2):147-54. PubMed ID: 24601805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.